Recombinant human interleukin-2 corrects NK cell phenotype and functional activity in patients with post-COVID syndrome
Open Access
- 4 September 2024
- journal article
- Published by ECO-Vector LLC in Cytokines and inflammation
- Vol. 20 (4) , 49-66
Abstract
Post-COVID syndrome develops in 10–20% of people who have recovered from COVID-19 and it is characterized by impaired function of the nervous, cardiovascular, and immune systems. Previously, it was found that patients who recovered from infection with the SARS-CoV-2 virus had a decrease in the number and functional activity of NK cells. The aim of the study was to assess the effectiveness of recombinant human interleukin-2 administered to correct NK cell phenotype and functional activity in patients with post-COVID syndrome. Patients were examined after 3 months for acute COVID-19 of varying severity. The phenotype of the peripheral blood NK cells was studied by flow cytometry. It was found that disturbances in the cell subset composition in patients with post-COVID syndrome were characterized by low levels of mature (p=0.001) and cytotoxic NK cells (p=0.013), with increased release of immature NK cells (p=0.023). Functional deficiency of NK cells in post-COVID syndrome was characterized by lowered cytotoxic activity due to the decreased count of CD57+ (p=0.001) and CD8+ (p 0.001) NK cells. In the treatment of patients with post-COVID syndrome with recombinant human interleukin-2, peripheral blood NK cell count and functional potential were restored. In general, the effectiveness of using recombinant human interleukin in treatment of post-COVID syndrome has been proven in patients with low levels of NK cells. This article is a translation of the article by Savchenko AA, Kudryavtsev IV, Isakov DV, Sadowski IS, Belenyuk VD, Borisov AG. Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. Pharmaceuticals. 2023;16(4):537. DOI: 10.3390/ph16040537 Published with the permission of the copyright holder.Keywords
This publication has 58 references indexed in Scilit:
- Characterization of memory T cell subsets and common γ−chain cytokines in convalescent COVID-19 individualsJournal of Leukocyte Biology, 2022
- Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post‐acute sequelae of SARS‐CoV‐2 infection (PASC)PM&R, 2021
- Post‐COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross‐sectional evaluation from a community COVID rehabilitation serviceJournal of Medical Virology, 2021
- The COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS): Application and psychometric analysis in a post‐COVID‐19 syndrome cohortJournal of Medical Virology, 2021
- The coagulopathy, endotheliopathy, and vasculitis of COVID-19Inflammation Research, 2020
- COVID-19 and Cancer: a Comprehensive ReviewCurrent Oncology Reports, 2020
- Loss of NKG2D in murine NK cells leads to increased perforin production upon long‐term stimulation with IL‐2European Journal of Immunology, 2020
- IL-2 mediates NK cell proliferation but not hyperactivityImmunologic Research, 2017
- CD57 in human natural killer cells and T-lymphocytesCancer Immunology, Immunotherapy, 2016
- OMIP‐007: Phenotypic analysis of human natural killer cellsCytometry Part A, 2012